Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276:36869–72.

Article  CAS  PubMed  Google Scholar 

Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017;97:1045–87.

Article  PubMed  Google Scholar 

Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358–417.

Article  CAS  PubMed  Google Scholar 

Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23:232–54.

PubMed  PubMed Central  Google Scholar 

Jia M, Dahlman-Wright K, Gustafsson JÅ. Estrogen receptor alpha and beta in health and disease. Best Pr Res Clin Endocrinol Metab. 2015;29:557–68.

Article  CAS  Google Scholar 

McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrinol Metab. 1999;10:301–11.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology guideline. JCO. 2016;34:3069–103.

Article  CAS  Google Scholar 

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7:277–87.

Article  CAS  PubMed  Google Scholar 

Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med. 2014;24:329–42.

Article  Google Scholar 

Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29:2905–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18:1859–75.

Article  PubMed  Google Scholar 

Mao C, Patterson NM, Cherian MT, Aninye IO, Zhang C, Montoya JB, et al. A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem. 2008;283:12819–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Stuart W, Hu B, Nguyen L, Huang G, Clemens TL, et al. Creation of estrogen resistance in vivo by transgenic overexpression of the heterogeneous nuclear ribonucleoprotein-related estrogen response element binding protein. Endocrinology. 2005;146:4266–73.

Article  CAS  PubMed  Google Scholar 

Chen H, Hewison M, Adams JS. Control of estradiol-directed gene transactivation by an intracellular estrogen-binding protein and an estrogen response element-binding protein. Mol Endocrinol. 2008;22:559–69.

Article  CAS  PubMed  Google Scholar 

Chen H, Clemens TL, Hewison M, Adams JS. Estradiol and tamoxifen mediate rescue of the dominant-negative effects of estrogen response element-binding protein in vivo and in vitro. Endocrinology. 2009;150:2429–35.

Article  CAS  PubMed  Google Scholar 

Dixon JM. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert Rev Anticancer Ther. 2002;2:267–75.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23:382–92.

Article  Google Scholar 

Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268:1766–9.

Article  CAS  PubMed  Google Scholar 

Austin S, Ziese M, Sternberg N. A novel role for site-specific recombination in maintenance of bacterial replicons. Cell. 1981;25:729–36.

Article  CAS  PubMed  Google Scholar 

Huang J, Li X, Yi P, Hilf R, Bambara RA, Muyan M. Targeting estrogen-responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol Cell Endocrinol. 2004;218:65–78.

Article  CAS  PubMed  Google Scholar 

Kuntz MA, Shapiro DJ. Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements. J Biol Chem. 1997;272:27949–56.

Article  CAS  PubMed  Google Scholar 

Shui S, Wang S, Liu J. Systematic investigation of the effects of multiple SV40 nuclear localization signal fusion on the genome editing activity of purified SpCas9. Bioengineering. 2022;9:83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493–500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296:1642–4.

Article  CAS  PubMed  Google Scholar 

Welboren WJ, Sweep FCGJ, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer. 2009;16:1073–89.

Article  CAS  PubMed  Google Scholar 

Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–73.

CAS  PubMed  Google Scholar 

Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA. 1986;83:2496–2500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Utomo AR, Nikitin AY, Lee WH. Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. Nat Biotechnol. 1999;17:1091–6.

Article